Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence

Area of Science:

• Oncology
• Neuro-oncology
• Molecular Biology

Background:

• Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brainstem tumor with significant therapeutic resistance.
• Current treatments for DIPG, including radiotherapy, often fail to prevent tumor progression, necessitating novel therapeutic strategies.
• Understanding resistance mechanisms is crucial for developing effective treatments that penetrate the blood-brain barrier.

Purpose of the Study:

• To identify mechanisms of radiotherapy resistance in DIPG.
• To design and evaluate a novel brain-penetrant small molecule inhibitor, MTX-241F, targeting key resistance pathways.
• To explore the efficacy of MTX-241F in combination with radiotherapy and DNA repair inhibitors for DIPG treatment.

Main Methods:

• Identification of DIPG resistance mechanisms to radiotherapy.
• Rational design of MTX-241F, a selective inhibitor of EGFR, PI3K family members, and DNA-PK.
• Assessment of MTX-241F brain penetrance and single-agent efficacy in preclinical models.
• Evaluation of combination therapies involving MTX-241F, radiotherapy, and DNA repair inhibitors (ATM inhibitors).

Main Results:

• MTX-241F demonstrated excellent brain penetrance, achieving micromolar concentrations in murine brain tissue.
• MTX-241F showed promising single-agent efficacy and radiosensitizing activity in patient-derived DIPG neurospheres.
• Combination therapy with MTX-241F, radiotherapy, and homologous recombination blockers resulted in synthetic lethality in DIPG models.

Conclusions:

• MTX-241F is a promising brain-penetrant therapeutic candidate for DIPG.
• The combination of MTX-241F with radiotherapy and DNA repair pathway inhibitors offers a novel strategy to overcome therapeutic resistance.
• These findings provide proof-of-concept for advanced development and clinical translation of MTX-241F for DIPG treatment.